Literature DB >> 12100149

Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production.

Agata Kosmaczewska1, Irena Frydecka, Dorota Boćko, Lidia Ciszak, Renata Teodorowska.   

Abstract

Expression of the downregulatory CTLA-4 molecule was determined on unstimulated and anti-CD3 + recombinant interleukin 2 (rIL-2)-stimulated peripheral blood T cells in Hodgkin's disease (HD) and correlated with the T-cells' proliferative activity, IL-2 and interferon (IFN)-gamma production. There was a negligible percentage of CTLA-4+/CD3+ cells before culture. The mean percentage of CTLA-4+/CD3+ lymphocytes increased gradually, peaked after 72 h of stimulation and returned to basal values after 96 h of stimulation. The mean proportion of CTLA-4+/CD3+ cells from untreated patients was significantly higher after 24, 48 and 72 h of stimulation compared with controls. The mean percentage of CTLA-4+/CD3+ cells from patients in clinical remission (CR) was lower than that of untreated patients, but remained significantly higher compared with controls. Lymphocytes from untreated HD patients showed impaired proliferative activity, IL-2 and IFN-gamma production compared with controls. The proliferative activity of the lymphocytes, IL-2 and IFN-gamma production remained significantly lower in CR compared with controls. The proportion of CTLA-4+/CD3+ cells negatively correlated with proliferative activity, IL-2 and IFN-gamma production in HD patients and controls. However, some untreated patients as well as patients in CR with normal mean fluorescence intensity values of CTLA-4 showed unimpaired T-cell function tests. Our study provides the first evidence of an increased expression of downregulatory CTLA-4 molecule on stimulated T-cells in HD, which could be one of the mechanisms of immune deficiency in this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100149     DOI: 10.1046/j.1365-2141.2002.03572.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors:  Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

2.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

Review 3.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

4.  Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression.

Authors:  Agata Kosmaczewska; Dorota Bocko; Lidia Ciszak; Iwona Wlodarska-Polinska; Jan Kornafel; Aleksandra Szteblich; Anna Masternak; Irena Frydecka
Journal:  Pathol Oncol Res       Date:  2011-11-19       Impact factor: 3.201

Review 5.  Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Authors:  Jodi Chiu; Daniel M Ernst; Armand Keating
Journal:  Front Immunol       Date:  2018-02-14       Impact factor: 7.561

6.  Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia.

Authors:  I Frydecka; A Kosmaczewska; D Bocko; L Ciszak; D Wolowiec; K Kuliczkowski; I Kochanowska
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

7.  HLA-G peptide preferences change in transformed cells: impact on the binding motif.

Authors:  Alexander A Celik; Gwendolin S Simper; Wiebke Hiemisch; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2018-03-30       Impact factor: 2.846

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.